Adam Laponis Sells 4,160 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis sold 4,160 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $185,536.00. Following the completion of the transaction, the chief financial officer now directly owns 89,237 shares of the company’s stock, valued at approximately $3,979,970.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Adam Laponis also recently made the following trade(s):

• On Wednesday, October 9th, Adam Laponis sold 856 shares of Twist Bioscience stock. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36.

Twist Bioscience Stock Performance

TWST opened at $45.40 on Friday. The company has a 50-day moving average of $43.69 and a 200-day moving average of $45.64. The company has a market capitalization of $2.66 billion, a P/E ratio of -11.88 and a beta of 1.78. Twist Bioscience Co. has a 1-year low of $15.85 and a 1-year high of $60.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TWST. Thrivent Financial for Lutherans acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at about $43,992,000. Point72 Asset Management L.P. boosted its stake in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC raised its position in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after buying an additional 575,080 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after buying an additional 300,891 shares in the last quarter. Finally, Farallon Capital Management LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $9,462,000.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TWST shares. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Barclays cut their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.